The Children's Oncology Group (COG) Statistics and Data Center (SDC), collaborates with the COG membership to design, conduct analyze and report the results of clinical trials of the treatment of childhood cancers and associated, laboratory-based, companion studies of the biology of these malignancies. Specifically, COG SDC personnel: Participate in the setting and evaluation of COG research priorities; collaborate in the development of study concepts and protocols. In particular, members of the SDC develop the study's statistical considerations; collaborate in the development and implementation of the study's case- report forms for the Group's clinical data management system; monitor study enrollment and the quality and completeness of study data submission; produce interim reports on study conduct and adverse event experience for the Group membership and protocol-specified interim analyses of study outcomes for the Group's Data and Safety Monitoring Committees; produce final reports of the study results for the Group membership; collaborate with laboratories to link specimen data and high dimensional genomics data with COG clinical and outcome data and to produce analyses of these data for publication; produce Technical Reports, detailing analyses performed for Group abstracts and manuscripts; conduct database and methodological research of relevance to the Group's research; perform CDUS and results reporting; monitor the performance of COG member institutions, producing reports for the Group's Institutional Performance monitoring Committee; provide data derived from COG studies to investigators external to the SDC in accordance with the policies and procedures of the Group; participate in National Clinical Trials Network initiatives and CTEP committees as appropriate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180899-04
Application #
9251746
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-15
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Florida
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Stockard, Bradley; Garrett, Timothy; Guingab-Cagmat, Joy et al. (2018) Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. Sci Rep 8:5534
Fernandez, Conrad V; Mullen, Elizabeth A; Chi, Yueh-Yun et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 36:254-261
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Aldrink, Jennifer H; Appel, Burton; Kaplan, Joel A et al. (2018) Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. J Pediatr Hematol Oncol 40:246-247
Burke, Michael J; Devidas, Meenakshi; Maloney, Kelly et al. (2018) Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma 59:1624-1633
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Urtishak, Karen A; Wang, Li-San; Culjkovic-Kraljacic, Biljana et al. (2018) Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene :
Mullen, Elizabeth A; Chi, Yueh-Yun; Hibbitts, Emily et al. (2018) Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol :JCO1800076
Ariƫs, Ingrid M; Bodaar, Kimberly; Karim, Salmaan A et al. (2018) PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 215:3094-3114

Showing the most recent 10 out of 317 publications